Boston becomes CTO treatment leader with BridgePoint acquisition
This article was originally published in Clinica
Executive Summary
Boston Scientific claims to have become number one in the treatment of chronic total occlusions (CTOs) with the acquisition of BridgePoint Medical for an undisclosed fee. BridgePoint gives Boston a coronary CTO treatment offering to add to its existing peripheral CTO devices.